Zimmer Biomet Holdings, Inc. Earnings Recaps
Q1 2026
Apr 29, 2026
Zimmer Biomet shares fell 13.5% after Q1 as investors reacted negatively to a cautious full-year outlook and evidence of ongoing revenue deceleration, despite in-line results for the quarter. The reaffirmed 2026 guidance of 1–3% organic growth—with continued pricing pressure and commercial transition disruptions—disappointed the market.
Key takeaways
- Q1 organic sales grew 2.9% and U.S. sales rose 3.2%, but management reiterated full-year organic growth guidance at just 1–3%, implying deceleration ahead.
- Adjusted EPS for the quarter was $2.09, up 15% year-over-year, with a $0.20 benefit from favorable tariff actions.
- U.S. knee growth remained muted at 2.2%, with pressure from legacy product phase-outs; international knees grew just 1.3%.
- Management cited ongoing disruption from commercial transitions and maintained assumptions for up to 100 basis points of price erosion in 2026.
- Technology-driven segments like surgical and robotics posted near-12% growth, but these positives were overshadowed by continued challenges in restorative therapies and trauma.
Q3 2025
Nov 6, 2025
Zimmer Biomet reported a 5% organic sales growth in Q3 2025, driven by strong U.S. performance, although impacted by weakness in international markets and certain product segments.
Key takeaways
- U.S. sales accelerated to 5.6% growth, marking the highest quarterly performance since mid-2023, while technology and data sales surged by 20.3%.
- The company’s new products, such as Persona OsseoTi and robotics solutions, gained significant market traction, with U.S. knee implants performed robotically increasing 400 basis points year-over-year.
- Full-year revenue growth guidance revised to 3.5% to 4%, reflecting challenges in restorative therapies and a slowdown in the revision market, while adjusted EPS guidance remains at $8.10 to $8.30.